Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00911729 |
Recruitment Status :
Terminated
First Posted : June 2, 2009
Last Update Posted : June 10, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Pheochromocytoma Paraganglioma |
Study Type : | Observational |
Estimated Enrollment : | 24 participants |
Observational Model: | Case-Only |
Time Perspective: | Cross-Sectional |
Official Title: | Content Validation of the EORTC QLQ-C30 Version 3.0, and NIH Quality of Life and Symptoms Questionnaire for Pheochromocytoma and Paraganglioma |
Study Start Date : | April 2009 |

- The main objective of this study is to evaluate content validity of the NIH Quality of Life and Symptoms Questionnaire for Pheochromocytoma and Paraganglioma and EORTC-QLQ-C30 in patients with pheochromocytoma or paraganglioma. [ Time Frame: Single Visit ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Provide written informed consent and be willing to comply with protocol requirements
- Participant is aged ≥ 18
- Have a documented (medical record) diagnosis of either pheochromocytoma or paraganglioma with active symptoms or within 60 days of curative therapy
Exclusion Criteria:
Patient is currently asymptomatic from pheochromocytoma/paraganglioma diagnosis or duration > 60 days from curative therapy
- Participant has a clinically significant disorder, including alcohol or drug abuse, which may interfere with study participation or which may affect the outcome of the study as judged by the investigator.
- Participant has a mental disability or significant mental illness, legal incapacity or limited legal capacity or any other lack of fitness, in the investigator's opinion, to preclude the subject's participation in or ability to complete the study.
- Participant is currently too unwell to take part in the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00911729
United States, Maryland | |
Oxford Outcomes- Nationwide Recruitment within the US | |
Bethesda, Maryland, United States, 20814 |
Principal Investigator: | Emuella M Flood, BS | Oxford Outcomes |
Responsible Party: | Meredith Frank-Molnia, Molecular Insight Pharmaceuticals, Inc |
ClinicalTrials.gov Identifier: | NCT00911729 |
Other Study ID Numbers: |
A1970 |
First Posted: | June 2, 2009 Key Record Dates |
Last Update Posted: | June 10, 2013 |
Last Verified: | June 2013 |
paraganglioma pheochromocytoma |
Pheochromocytoma Paraganglioma Carotid Body Tumor Neuroendocrine Tumors Neuroectodermal Tumors |
Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Paraganglioma, Extra-Adrenal |